Pharmaron Beijing Co., Ltd. Class H (HK:3759)
:3759
Want to see HK:3759 full AI Analyst Report?
Top Page
Pharmaron Beijing Co., Ltd. Class H
(3759)
Select Model
Select Model
Rating:68Neutral
Price Target:
HK$16.50
â–¼(-31.65% Downside)
Action:Reiterated
Date:04/30/26
The score is driven mainly by solid profitability and a healthier, low-leverage balance sheet, offset by weak and volatile free-cash-flow conversion. Technicals add moderate support with improving shorter-term momentum, while valuation is acceptable but not compelling and the dividend is modest.
Positive Factors
Integrated CDMO/R&D model
Pharmaron's end-to-end service offering (discovery through manufacturing) creates durable client stickiness and multiple cross-sell touchpoints. Contractual, fee-for-service revenue across stages diversifies income sources and supports long-term client lifetime value and repeat business.
Negative Factors
Weak and volatile free cash flow
Sharp decline and low FCF-to-income ratio indicate weak cash conversion and potential working-capital or reinvestment pressures. Persistent FCF volatility limits capacity to self-fund expansion, reduces buffer for downturns, and increases reliance on external capital for growth or M&A.
Read all positive and negative factors
Positive Factors
Negative Factors
Integrated CDMO/R&D model
Pharmaron's end-to-end service offering (discovery through manufacturing) creates durable client stickiness and multiple cross-sell touchpoints. Contractual, fee-for-service revenue across stages diversifies income sources and supports long-term client lifetime value and repeat business.
Read all positive factors
Pharmaron Beijing Co., Ltd. Class H (3759) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$43.59B
Dividend Yield1.04%
Average Volume (3M)3.76M
Price to Earnings (P/E)24.2
Beta (1Y)2.01
Revenue Growth16.83%
EPS Growth-8.65%
CountryHK
Employees21,370
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.95
Shares Outstanding359,977,870
10 Day Avg. Volume3,469,725
30 Day Avg. Volume3,761,430
Financial Highlights & Ratios
PEG Ratio-2.70
Price to Book (P/B)2.06
Price to Sales (P/S)2.20
P/FCF Ratio56.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$29.03Price Target Upside20.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)1.27
Revenue Forecast (FY)HK$18.64B
Pharmaron Beijing Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Pharmaron Beijing Co., Ltd. is a global contract research, development, and manufacturing organization (CRDMO) that supports the life sciences sector. Operating across North America, Europe, Mainland China, and other Asian regions, the company del...
How the Company Makes Money
Pharmaron makes money primarily by providing fee-for-service, contract-based R&D and manufacturing services to pharmaceutical and biotechnology clients. Key revenue streams typically include: (1) Laboratory research and discovery services (e.g., c...
Pharmaron Beijing Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
78
Positive
Cash Flow
52
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.43B | 14.10B | 12.28B | 11.54B | 10.27B | 7.44B |
| Gross Profit | 4.96B | 4.91B | 4.20B | 4.12B | 3.77B | 2.68B |
| EBITDA | 2.39B | 3.29B | 3.38B | 2.95B | 2.53B | 2.49B |
| Net Income | 1.69B | 1.66B | 1.79B | 1.60B | 1.37B | 1.66B |
Balance Sheet | ||||||
| Total Assets | 28.47B | 27.09B | 23.93B | 26.48B | 20.49B | 18.39B |
| Cash, Cash Equivalents and Short-Term Investments | 2.97B | 1.73B | 2.81B | 6.72B | 2.24B | 5.10B |
| Total Debt | 7.08B | 3.42B | 5.54B | 9.36B | 6.12B | 5.29B |
| Total Liabilities | 11.41B | 11.36B | 9.70B | 13.24B | 9.65B | 8.09B |
| Stockholders Equity | 16.40B | 15.06B | 13.62B | 12.56B | 10.55B | 10.13B |
Cash Flow | ||||||
| Free Cash Flow | 304.88M | 551.97M | 536.02M | -111.78M | -807.04M | -34.78M |
| Operating Cash Flow | 3.01B | 3.22B | 2.58B | 2.75B | 2.14B | 2.06B |
| Investing Cash Flow | -3.45B | -4.37B | -2.02B | -2.25B | -2.21B | -5.26B |
| Financing Cash Flow | 1.57B | 377.00M | -4.80B | 3.92B | -1.42B | 3.66B |
Pharmaron Beijing Co., Ltd. Class H Technical Analysis
Negative
24.14
Price Trends
18.77
Negative
19.35
Negative
21.46
Negative
Market Momentum
-1.05
Positive
30.79
Neutral
28.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3759, the sentiment is Negative. The current price of 24.14 is above the 20-day moving average (MA) of 16.45, above the 50-day MA of 18.77, and above the 200-day MA of 21.46, indicating a bearish trend. The MACD of -1.05 indicates Positive momentum. The RSI at 30.79 is Neutral, neither overbought nor oversold. The STOCH value of 28.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:3759.
Pharmaron Beijing Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | HK$50.24B | 40.40 | 6.34% | 1.57% | 18.78% | 12.65% | |
68 Neutral | HK$43.59B | 24.18 | 11.22% | 1.04% | 16.83% | -8.65% | |
64 Neutral | HK$127.68B | 22.86 | 10.64% | ― | 16.79% | 47.14% | |
54 Neutral | HK$25.67B | -6.15 | -12.72% | ― | ― | ― | |
52 Neutral | HK$2.39B | 11.09 | 5.57% | ― | -12.90% | 33.65% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$2.14B | 40.13 | 1.98% | ― | 0.61% | 766.67% |
* Healthcare Sector Average
HK:3759
Pharmaron Beijing Co., Ltd. Class H
15.22
-0.21
-1.39%
HK:1548
Genscript Biotech
11.79
-3.03
-20.45%
HK:2269
Wuxi Biologics (Cayman)
30.82
6.32
25.80%
HK:1521
Frontage Holdings Corp.
1.05
-0.13
-11.02%
HK:1873
Viva Biotech Holdings
1.13
-0.41
-26.62%
HK:6821
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
94.15
22.87
32.08%
Pharmaron Beijing Co., Ltd. Class H Corporate Events
Pharmaron Reshapes Board Committees to Bolster Governance and Strategy
Jun 15, 2026
Pharmaron Beijing Co., Ltd. has announced the composition of its fourth session board of directors, naming executive, non-executive, independent and employee representative directors, with Dr. Lou Boliang serving as chairman. The company has also ...
Pharmaron Shareholders Approve 2025 AGM Resolutions, Dividend Plan and Governance Changes
Jun 12, 2026
Pharmaron Beijing Co., Ltd. reported the results of its 2025 annual general meeting in Beijing, confirming that the meeting was validly convened under PRC law and its Articles of Association, with about 48.7% of voting shares represented. All dire...
Pharmaron Beijing Sets New Board Line-Up and Prepares Committee Appointments
Jun 12, 2026
Pharmaron Beijing Co., Ltd. has outlined the composition of its new board of directors, naming executive, non-executive, independent non-executive and employee representative directors to oversee the company. The move formalizes its governance fra...
Pharmaron Sets Updated Final Cash Dividend and Clarifies Tax Treatment for 2025
Jun 12, 2026
Pharmaron Beijing Co., Ltd. has announced an updated final cash dividend for the financial year ended 31 December 2025, setting the distribution at RMB 2 per 10 shares, with Hong Kong shareholders receiving HKD 2.299274 per 10 shares based on an e...
Pharmaron Beijing Names CFO Li Shing Chung Gilbert as Employee Representative Director
Jun 5, 2026
Pharmaron Beijing has appointed chief financial officer and board secretary Li Shing Chung Gilbert as the employee representative director for its fourth board session, following his election at an employee representatives’ meeting on 5 June...
Pharmaron to Invest RMB2 Billion in New Hangzhou CDMO and API Facility
May 27, 2026
Pharmaron Beijing Co., Ltd. has signed an investment agreement with Hangzhou Qiantang Investment Service Center to build a new commercial drug production and CDMO RD facility in Qiantang District, Hangzhou. The project, with an expected total inve...
Pharmaron to Invest RMB3 Billion in New Shaoxing API Manufacturing Hub
May 27, 2026
Pharmaron Beijing Co., Ltd. plans to invest about RMB3.0 billion through its wholly owned subsidiary Pharmaron Shaoxing to build new facilities in Shaoxing, Zhejiang, with an annual capacity of 200 tonnes of high-end pharmaceutical intermediates a...
Pharmaron Sets Timetable and Tax Terms for 2025 Final Cash Dividend
May 21, 2026
Pharmaron Beijing Co., Ltd. has updated details of its proposed final cash dividend for the financial year ended 31 December 2025, setting the payout at RMB 2 per 10 shares, subject to shareholder approval at the annual general meeting on 12 June ...
Pharmaron Sets 2025 AGM to Approve Board Changes, Capital Increase and Governance Updates
May 21, 2026
Pharmaron Beijing Co., Ltd. has called its 2025 annual general meeting for June 12, 2026 in Beijing, where shareholders will review the 2025 board work report, profit distribution and 2026 interim dividend plan, the 2025 annual report, director re...
Pharmaron Beijing Reshapes Board Structure Ahead of Fourth Session
Apr 28, 2026
Pharmaron Beijing has proposed a new eight-member fourth-session board structure, reducing the number of directors from nine to eight to improve decision-making efficiency and corporate governance. The slate includes three executive directors, one...
Pharmaron Beijing Issues Unaudited First-Quarter 2026 Report Under Hong Kong Rules
Apr 28, 2026
Pharmaron Beijing Co., Ltd. has released its unaudited first quarterly report for 2026, prepared primarily under PRC Accounting Standards, with certain sections aligned to International Financial Reporting Standards. The disclosure, made in accord...
Pharmaron Beijing Sets Board Meeting to Approve First-Quarter 2026 Results
Apr 14, 2026
Pharmaron Beijing Co., Ltd. has scheduled a meeting of its board of directors for April 28, 2026, to review and approve the first quarterly results for the three months ended March 31, 2026. The board will also consider the formal publication of t...
Pharmaron Lifts Revenue and Cash Flow in 2025 Despite Profit Dip
Mar 30, 2026
Pharmaron Beijing Co., Ltd. reported 2025 revenue of RMB14.10 billion, up 14.8% year on year, driven by continued expansion of its contract research and manufacturing services for global pharmaceutical clients. Despite higher administrative and RD...
Pharmaron Beijing Plans 2025 Final Cash Dividend Payout
Mar 30, 2026
Pharmaron Beijing Co., Ltd. has proposed a final ordinary cash dividend of RMB 2 per 10 shares for the financial year ended 31 December 2025, with the Hong Kong dollar equivalent, key dates, and applicable withholding tax details to be announced. ...
Pharmaron Beijing Revamps Governance Roles and Formalizes Registered Capital Increase
Mar 30, 2026
Pharmaron Beijing announced a management reshuffle, with company secretary and authorised representative Mr. Yim Lok Kwan resigning effective March 30, 2026, and experienced governance professional Ms. Mak Po Man Cherie stepping in as company secr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.